Compare DG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DG | MRNA |
|---|---|---|
| Founded | 1939 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4B | 21.6B |
| IPO Year | 2008 | 2018 |
| Metric | DG | MRNA |
|---|---|---|
| Price | $103.26 | $47.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 12 |
| Target Price | ★ $139.60 | $34.27 |
| AVG Volume (30 Days) | 3.8M | ★ 6.8M |
| Earning Date | 06-02-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | ★ 34.05 | 21.77 |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $42,724,369,000.00 | $19,263,000,000.00 |
| Revenue This Year | $7.14 | $9.36 |
| Revenue Next Year | $4.17 | $15.43 |
| P/E Ratio | $51.75 | ★ N/A |
| Revenue Growth | ★ 5.20 | 4.29 |
| 52 Week Low | $95.11 | $22.28 |
| 52 Week High | $158.23 | $59.55 |
| Indicator | DG | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 45.61 |
| Support Level | $97.88 | $46.13 |
| Resistance Level | $107.15 | $55.36 |
| Average True Range (ATR) | 4.55 | 2.65 |
| MACD | 0.42 | 0.18 |
| Stochastic Oscillator | 23.72 | 35.25 |
Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.